InnovHeart s.r.l. develops Transcatheter Mitral Valve Replacement (TMVR) systems to treat mitral valve disease, notably its Saturn low-profile mitral heart valve designed for trans-apical or trans-septal delivery. The company has reported excellent mid-term (>1 year) results with the trans-apical version of Saturn and is conducting clinical trials of the system. InnovHeart intends to advance a trans-septal version of the Saturn system into first-in-human clinical trials in 2022. In January 2022 it closed a Series C financing tied to an exclusive licensing agreement in Greater China. The transaction included more than $55 million in equity plus upfront licensing fees, milestone payments and structured royalties to support development and commercialization. InnovHeart has locations in Milan, Italy and Newton, Massachusetts, USA. InnovHeart develops the Saturn transcatheter mitral valve replacement (TMVR) system, a low-profile mitral heart valve designed for trans‑apical and trans‑septal delivery. The company is advancing its Saturn system toward First‑in‑Human clinical evaluation using a trans‑apical approach. Proceeds from the recent financing will also support finalizing the trans‑septal delivery system that uses the same valve technology. InnovHeart maintains offices outside Milan, Italy, and in Newton, Massachusetts. The company was founded in 2015 and has been conducting clinical trials of its Saturn TMVR system. Leadership highlights include board chair Keith D. Dawkins, MD, and the addition of Barbara Castellano to the board representing an investor.

Total raised

$79M

Funding rounds

2

Latest round

Series C

Latest activity

Jan 2022